Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
15.69(c) 14.04(c) 13.94(c) 14.32(c) 13.41(c) Last
130 543 154 259 123 115 90 431 64 871 Volume
+0.90% -10.52% -0.71% +2.73% -6.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 75,9 M - -
Net income 2021 -131 M - -
Net cash position 2021 127 M - -
P/E ratio 2021 -2,93x
Yield 2021 -
Sales 2022 45,6 M - -
Net income 2022 -194 M - -
Net cash position 2022 23,4 M - -
P/E ratio 2022 -2,61x
Yield 2022 -
Capitalization 409 M 409 M -
EV / Sales 2021 3,71x
EV / Sales 2022 8,46x
Nbr of Employees 137
Free-Float 95,0%
More Financials
Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its focuses on diseases for which the unmet medical need is high and the biology for treatment is clear. Its pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential... 
More about the company
Ratings of Mirum Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about MIRUM PHARMACEUTICALS, INC.
11/22Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
11/19MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statem..
AQ
11/18Longeveron Shares Soar 120% on Key FDA Designation
DJ
11/17Mirum to Sell Livmarli Priority Review Voucher for $110 Million
MT
11/17Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
BU
11/15MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/15MIRUM PHARMACEUTICALS : Reports Third Quarter 2021 Financial Results and Provides Business..
PU
11/15Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/15Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
BU
11/15Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Ev..
BU
11/15Mirum Pharmaceuticals, Inc. Announces That A New Analysis Comparing Pooled Livmarli? (M..
CI
11/08Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conferenc..
BU
11/01Mirum Pharmaceuticals to Present Maralixibat Data at Scientific Conference
MT
11/01New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting« 2021
BU
11/01The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixib..
BU
More news
News in other languages on MIRUM PHARMACEUTICALS, INC.
11/17Mirum vendra le coupon d'évaluation prioritaire de Livmarli pour 110 millions de dollar..
11/01Mirum Pharmaceuticals présentera des données sur le Maralixibat lors d'une conférence s..
09/29Mirum Pharmaceuticals obtient l'autorisation de la FDA pour la solution orale Livmarli ..
09/21Mirum s'associe à Takeda pour développer et commercialiser un candidat médicament contr..
04/13MIRUM PHARMACEUTICALS : et Vivet Therapeutics concluent un accord mondial exclusif d'optio..
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 13,41 $
Average target price 54,71 $
Spread / Average Target 308%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.-23.20%409
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431